Entrada Therapeutics, Inc
Price
FilingsNewest: 10-Q, Quarterly reportAug 5 →Insiders5 insiders bought $1.6M in 17 open-market buys. 23 insiders sold $15.1M, 9 of 44 sales on a 10b5-1 plan.→HoldersBaker Bros 13.0%5AM Venture 10.4%BlackRock 6.6%→Financing →PeersClosest companies: PEPG, SEPN, DYN→
From the filings
Figures
- Revenue
- $4.7Mlast 12 months
- Net income
- −$165.8Mlast 12 months
- Operating cash flow
- −$131.7Mlast 12 months
- Cash and equivalents
- $99.3Mat the last balance sheet
- Shares outstanding
- 38.9M shareson issue